The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

VIPR1  -  vasoactive intestinal peptide receptor 1

Homo sapiens

Synonyms: HVR1, II, PACAP type II receptor, PACAP-R-2, PACAP-R2, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of VIPR1


Psychiatry related information on VIPR1


High impact information on VIPR1


Chemical compound and disease context of VIPR1


Biological context of VIPR1


Anatomical context of VIPR1


Associations of VIPR1 with chemical compounds

  • Ro 25-1392 evoked concurrent and concentration-dependent increases in intracellular levels of calcium and cyclic AMP (EC50 = 3.0 +/- 0.4 nM, mean +/- S.E.M., n = 4) in VIPR2 transfectants, but not in VIPR1 transfectants [20].
  • Chenodeoxycholate also provoked an increase in VPAC1 mRNA and protein content in these cells [17].
  • In these cells, the FXR pharmacological agonist GW4064 upregulated VPAC1 expression in a dose-dependent manner, and this effect was antagonized by the RXRalpha ligand, 9-cis retinoic acid [17].
  • The VPAC1 receptor mediates the action of two neuropeptides, vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide [21].
  • Receptor-specific agonists were employed to determine which of the two known VIP receptor subtypes was involved in cortisol secretion [22].

Physical interactions of VIPR1

  • (iv) Taking into account the constraints provided by photoaffinity, VIP was docked into the hVPAC1 receptor N-ted [23].
  • This was confirmed using a cross-linking procedure to capture VIP receptor/G-protein complexes in the native membrane milieu prior to solubilization [24].

Regulatory relationships of VIPR1


Other interactions of VIPR1


Analytical, diagnostic and therapeutic context of VIPR1


  1. Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. Sreedharan, S.P., Huang, J.X., Cheung, M.C., Goetzl, E.J. Proc. Natl. Acad. Sci. U.S.A. (1995) [Pubmed]
  2. Solubilization of the active vasoactive intestinal peptide receptor from human colonic adenocarcinoma cells. el Battari, A., Martin, J.M., Luis, J., Pouzol, O., Secchi, J., Marvaldi, J., Pichon, J. J. Biol. Chem. (1988) [Pubmed]
  3. Chromosomal localization in mouse and human of the vasoactive intestinal peptide receptor type 2 gene: a possible contributor to the holoprosencephaly 3 phenotype. Mackay, M., Fantes, J., Scherer, S., Boyle, S., West, K., Tsui, L.C., Belloni, E., Lutz, E., Van Heyningen, V., Harmar, A.J. Genomics (1996) [Pubmed]
  4. Vasoactive intestinal peptide receptor regulation of cAMP accumulation and glycogen hydrolysis in the human Ewing's sarcoma cell line WE-68. Van Valen, F., Jürgens, H., Winkelmann, W., Keck, E. Cell. Signal. (1989) [Pubmed]
  5. Detection of VIP receptors in MNU-induced breast cancer in rats: implications for breast cancer targeting. Dagar, S., Sekosan, M., Rubinstein, I., Onyüksel, H. Breast Cancer Res. Treat. (2001) [Pubmed]
  6. AIDS and its dementia as a neuropeptide disorder: role of VIP receptor blockade by human immunodeficiency virus envelope. Pert, C.B., Smith, C.C., Ruff, M.R., Hill, J.M. Ann. Neurol. (1988) [Pubmed]
  7. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. Virgolini, I., Raderer, M., Kurtaran, A., Angelberger, P., Banyai, S., Yang, Q., Li, S., Banyai, M., Pidlich, J., Niederle, B., Scheithauer, W., Valent, P. N. Engl. J. Med. (1994) [Pubmed]
  8. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Vaudry, D., Gonzalez, B.J., Basille, M., Yon, L., Fournier, A., Vaudry, H. Pharmacol. Rev. (2000) [Pubmed]
  9. CD8(+) T-cell autoreactivity to an HLA-B27-restricted self-epitope correlates with ankylosing spondylitis. Fiorillo, M.T., Maragno, M., Butler, R., Dupuis, M.L., Sorrentino, R. J. Clin. Invest. (2000) [Pubmed]
  10. Importance of the vasoactive intestinal peptide receptor in the stimulation of cyclic adenosine 3',5'-monophosphate in gallbladder epithelial cells of man. Comparison with the guinea pig. Dupont, C., Broyart, J.P., Broer, Y., Chenut, B., Laburthe, M., Rosselin, G. J. Clin. Invest. (1981) [Pubmed]
  11. The vasoactive intestinal peptide receptor on intact human colonic adenocarcinoma cells (HT29-D4). Evidence for its glycoprotein nature. el Battari, A., Luis, J., Martin, J.M., Fantini, J., Muller, J.M., Marvaldi, J., Pichon, J. Biochem. J. (1987) [Pubmed]
  12. Effect of inhibiting N-glycosylation or oligosaccharide processing on vasoactive intestinal peptide receptor binding activity and structure. el Battari, A., Forget, P., Fouchier, F., Pic, P. Biochem. J. (1991) [Pubmed]
  13. Vasoactive intestinal peptide receptor expression on human lymphoblasts. O'Dorisio, M.S., Shannon, B.T., Mulne, A.F., Zwick, D., Grossman, N.J., Ruymann, F.B. The American journal of pediatric hematology/oncology. (1992) [Pubmed]
  14. Retinoic acid enhances VIP receptor expression and responsiveness in human neuroblastoma cell, SH-SY5Y. Waschek, J.A., Muller, J.M., Duan, D.S., Sadée, W. FEBS Lett. (1989) [Pubmed]
  15. Type 1 vasoactive intestinal peptide receptor expression in PC3/AR cells is evidence of prostate epithelial differentiation. Gkonos, P.J., Guo, F., Burnstein, K.L. Prostate (2000) [Pubmed]
  16. Similar involvement of VIP receptor type I and type II in lymphocyte chemotaxis. Schratzberger, P., Geiseler, A., Dunzendorfer, S., Reinisch, N., Kähler, C.M., Wiedermann, C.J. J. Neuroimmunol. (1998) [Pubmed]
  17. VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium. Chignard, N., Mergey, M., Barbu, V., Finzi, L., Tiret, E., Paul, A., Housset, C. Hepatology (2005) [Pubmed]
  18. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. Lara-Marquez, M., O'Dorisio, M., O'Dorisio, T., Shah, M., Karacay, B. J. Immunol. (2001) [Pubmed]
  19. Cloning and expression of the human vasoactive intestinal peptide receptor. Sreedharan, S.P., Robichon, A., Peterson, K.E., Goetzl, E.J. Proc. Natl. Acad. Sci. U.S.A. (1991) [Pubmed]
  20. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. Xia, M., Sreedharan, S.P., Bolin, D.R., Gaufo, G.O., Goetzl, E.J. J. Pharmacol. Exp. Ther. (1997) [Pubmed]
  21. Identification of cytoplasmic domains of hVPAC1 receptor required for activation of adenylyl cyclase. Crucial role of two charged amino acids strictly conserved in class II G protein-coupled receptors. Couvineau, A., Lacapere, J.J., Tan, Y.V., Rouyer-Fessard, C., Nicole, P., Laburthe, M. J. Biol. Chem. (2003) [Pubmed]
  22. Vasoactive intestinal peptide (VIP) stimulates cortisol secretion from the H295 human adrenocortical tumour cell line via VPAC1 receptors. Nicol, M.R., Cobb, V.J., Williams, B.C., Morley, S.D., Walker, S.W., Mason, J.I. J. Mol. Endocrinol. (2004) [Pubmed]
  23. Peptide Agonist Docking in the N-terminal Ectodomain of a Class II G Protein-coupled Receptor, the VPAC1 Receptor: PHOTOAFFINITY, NMR, AND MOLECULAR MODELING. Tan, Y.V., Couvineau, A., Murail, S., Ceraudo, E., Neumann, J.M., Lacapère, J.J., Laburthe, M. J. Biol. Chem. (2006) [Pubmed]
  24. Identification of G-proteins coupling to the vasoactive intestinal peptide receptor VPAC(1) using immunoaffinity chromatography: evidence for precoupling. Martin Shreeve, S. Biochem. Biophys. Res. Commun. (2002) [Pubmed]
  25. Pituitary adenylate cyclase-activating polypeptide stimulates secretion in T84 cells. Nguyen, T.D., Heintz, G.G., Cohn, J.A. Gastroenterology (1992) [Pubmed]
  26. Signal transduction through the vasoactive intestinal peptide receptor stimulates phosphorylation of the tyrosine kinase pp60c-src. Koh, S.W. Biochem. Biophys. Res. Commun. (1991) [Pubmed]
  27. Subset of cells immunopositive for neurokinin-1 receptor identified as arterial interstitial cells of Cajal in human large arteries. Bobryshev, Y.V. Cell Tissue Res. (2005) [Pubmed]
  28. Vasoactive intestinal peptide receptor-1 (VPAC-1) is a novel gene target of the hemolymphopoietic transcription factor Ikaros. Dorsam, G., Goetzl, E.J. J. Biol. Chem. (2002) [Pubmed]
  29. Shark rectal gland vasoactive intestinal peptide receptor: cloning, functional expression, and regulation of CFTR chloride channels. Bewley, M.S., Pena, J.T., Plesch, F.N., Decker, S.E., Weber, G.J., Forrest, J.N. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2006) [Pubmed]
  30. Molecular cloning and functional characterization of a human liver vasoactive intestinal peptide receptor. Gagnon, A.W., Aiyar, N., Elshourbagy, N.A. Cell. Signal. (1994) [Pubmed]
  31. Vasoactive intestinal peptide receptor activity and specificity during enterocyte-like differentiation and retrodifferentiation of the human colonic cancerous subclone HT29-18. Chastre, E., Emami, S., Rosselin, G., Gespach, C. FEBS Lett. (1985) [Pubmed]
  32. Structural and functional analysis of the human vasoactive intestinal peptide receptor glycosylation. Alteration of receptor function by wheat germ agglutinin. Chochola, J., Fabre, C., Bellan, C., Luis, J., Bourgerie, S., Abadie, B., Champion, S., Marvaldi, J., el Battari, A. J. Biol. Chem. (1993) [Pubmed]
  33. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. Reubi, J.C. J. Nucl. Med. (1995) [Pubmed]
  34. Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours. Hessenius, C., Bäder, M., Meinhold, H., Böhmig, M., Faiss, S., Reubi, J.C., Wiedenmann, B. European journal of nuclear medicine. (2000) [Pubmed]
WikiGenes - Universities